Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides sees NV-387 as a key defense against bird flu pandemic
08:44am, Monday, 23'rd Dec 2024
NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential bird flu pandemic caused by the H5N1 Influenza A vir
SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a pote
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America
01:28pm, Friday, 06'th Dec 2024
The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of
NanoViricides pushes NV-387 to Phase II trials
08:34am, Friday, 15'th Nov 2024
NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiti
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
12:00am, Monday, 04'th Nov 2024
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that A
SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that A
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
06:30am, Tuesday, 08'th Oct 2024
Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides
NanoViricides prepares for Phase II trials for antiviral NV-387
08:54am, Monday, 30'th Sep 2024
NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30,
NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement
08:44am, Thursday, 26'th Sep 2024
NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of first refusal on all antiviral drug developments. This agre
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
06:30am, Thursday, 26'th Sep 2024
SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today tha
NanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMI
11:30am, Saturday, 14'th Sep 2024
NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral. Diwan explained that NV-387, a host mimetic drug, works differ
NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX
08:51am, Monday, 26'th Aug 2024
NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients under the World Health Organization's Monitored Emergency Use
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
07:30am, Monday, 26'th Aug 2024
SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it i
